{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:59:52Z","timestamp":1793915992933,"version":"4.8.0"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Rev and Rep"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s12015-026-11156-y","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T09:18:59Z","timestamp":1779787139000},"page":"2671-2690","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Induced Pluripotent Stem Cell\u2013Derived NK Cells as an Off-the-Shelf Platform for Cancer Immunotherapy: Opportunities, Challenges, and Clinical Translation"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6130-7805","authenticated-orcid":false,"given":"Shiva Mosadegh","family":"Manshadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2442-0635","authenticated-orcid":false,"given":"Maryam","family":"Mehravar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2711-9277","authenticated-orcid":false,"given":"Abbas","family":"Hajifathali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3698-4342","authenticated-orcid":false,"given":"Elham","family":"Roshandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2213-8142","authenticated-orcid":false,"given":"Saeid","family":"Kaviani Jabali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"issue":"11","key":"11156_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e21776","volume":"9","author":"C Wang","year":"2023","unstructured":"Wang, C., Wang, J., Che, S., & Zhao, H. (2023). CAR-T cell therapy for hematological malignancies: History, status and promise. Heliyon, 9(11), Article e21776. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e21776","journal-title":"Heliyon"},{"issue":"1","key":"11156_CR2","doi-asserted-by":"publisher","DOI":"10.1515\/biol-2025-1179","volume":"20","author":"Y Wang","year":"2025","unstructured":"Wang, Y. (2025). Advances in cancer immunotherapy and future directions in personalized medicine. Open Life Sciences, 20(1), Article 20251179. https:\/\/doi.org\/10.1515\/biol-2025-1179","journal-title":"Open Life Sciences"},{"key":"11156_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.oor.2024.100652","volume":"12","author":"I Desai","year":"2024","unstructured":"Desai, I., Thakur, S., & Pagariya, P. (2024). Current advances in immunotherapy for cancer. Oral Oncology Reports, 12, Article 100652. https:\/\/doi.org\/10.1016\/j.oor.2024.100652","journal-title":"Oral Oncology Reports"},{"key":"11156_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.927153","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang, X., Zhu, L., Zhang, H., Chen, S., & Xiao, Y. (2022). Car-t cell therapy in hematological malignancies: Current opportunities and challenges. Frontiers in Immunology, 13, Article 927153. https:\/\/doi.org\/10.3389\/fimmu.2022.927153","journal-title":"Frontiers in Immunology"},{"issue":"4","key":"11156_CR5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner, R. C., & Sterner, R. M. (2021). CAR-T cell therapy: Current limitations and potential strategies. Blood Cancer Journal, 11(4), 69. https:\/\/doi.org\/10.1038\/s41408-021-00459-7","journal-title":"Blood Cancer Journal"},{"issue":"1","key":"11156_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01744-9","volume":"18","author":"MC Vo","year":"2025","unstructured":"Vo, M. C., Tran, V. D. H., Nguyen, V. T., Ruzimurodov, N., Trung, D. T., Kim, S. K., Jung, S. H., & Lee, J. J. (2025). Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: Why are approvals restricted to hematologic malignancies? Journal of Hematology & Oncology, 18(1), Article 91. https:\/\/doi.org\/10.1186\/s13045-025-01744-9","journal-title":"Journal of Hematology & Oncology"},{"key":"11156_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1500177","volume":"15","author":"KMN Farid","year":"2024","unstructured":"Farid, K. M. N., Bug, G., Schmitt, A., Lang, F., Schubert, M. L., Haberkorn, U., M\u00fcller-Tidow, C., Dreger, P., & Schmitt, M. (2024). GVHD after CAR T-cell therapy post allogeneic hematopoietic cell transplantation\u2014Successfully treated by extracorporeal photopheresis. Frontiers in Immunology, 15, Article 1500177. https:\/\/doi.org\/10.3389\/fimmu.2024.1500177","journal-title":"Frontiers in Immunology"},{"key":"11156_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1675807","volume":"16","author":"Y Hou","year":"2025","unstructured":"Hou, Y., Hu, S., Liu, C., Chen, X., Wang, Y., Li, Y., Fu, Z., Feng, C., Gong, Y., Liu, Z., & Peng, S. (2025). Beyond car-t cells: Exploring car-nk, car-m, and car-\u03b3\u03b4 t strategies in solid tumor immunotherapy. Frontiers in Immunology, 16, Article 1675807. https:\/\/doi.org\/10.3389\/fimmu.2025.1675807","journal-title":"Frontiers in Immunology"},{"issue":"4","key":"11156_CR9","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1093\/abt\/tbaf019","volume":"8","author":"Y Yu","year":"2025","unstructured":"Yu, Y., & Ho, M. (2025). CAR NK cell therapy for solid tumors: Potential and challenges. Antibody Therapeutics, 8(4), 275\u2013289. https:\/\/doi.org\/10.1093\/abt\/tbaf019","journal-title":"Antibody Therapeutics"},{"issue":"1","key":"11156_CR10","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41420-024-02077-1","volume":"10","author":"Y Zhong","year":"2024","unstructured":"Zhong, Y., & Liu, J. (2024). Emerging roles of CAR-NK cell therapies in tumor immunotherapy: Current status and future directions. Cell Death Discovery, 10(1), 318. https:\/\/doi.org\/10.1038\/s41420-024-02077-1","journal-title":"Cell Death Discovery"},{"key":"11156_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2025.104912","volume":"214","author":"F Zhang","year":"2025","unstructured":"Zhang, F., Soleimani Samarkhazan, H., Pooraskari, Z., & Bayani, A. (2025). Beyond CAR-T: Engineered NK cell therapies (Car-nk, nkces) in next-generation cancer immunotherapy. Critical Reviews in Oncology\/Hematology, 214, Article 104912. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104912","journal-title":"Critical Reviews in Oncology\/Hematology"},{"key":"11156_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1603757","volume":"16","author":"FD Dos Reis","year":"2025","unstructured":"Dos Reis, F. D., Saidani, Y., Mart\u00edn-Rubio, P., Sanz-Pamplona, R., Stojanovic, A., & Correia, M. P. (2025). CAR-NK cells: Harnessing the power of natural killers for advanced cancer therapy. Frontiers in Immunology, 16, Article 1603757. https:\/\/doi.org\/10.3389\/fimmu.2025.1603757","journal-title":"Frontiers in Immunology"},{"issue":"9","key":"11156_CR13","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00262-025-04106-z","volume":"74","author":"S Li","year":"2025","unstructured":"Li, S., Jing, J., Chen, Y., Chi, E., Wang, B., Xie, Z., Yang, W., Shen, H., & Pan, J. (2025). Precision sniper for solid tumors: CAR-NK cell therapy. Cancer Immunology Immunotherapy, 74(9), 275. https:\/\/doi.org\/10.1007\/s00262-025-04106-z","journal-title":"Cancer Immunology Immunotherapy"},{"issue":"10","key":"11156_CR14","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","volume":"21","author":"L Peng","year":"2024","unstructured":"Peng, L., Sferruzza, G., Yang, L., Zhou, L., & Chen, S. (2024). CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cellular & Molecular Immunology, 21(10), 1089\u20131108. https:\/\/doi.org\/10.1038\/s41423-024-01207-0","journal-title":"Cellular & Molecular Immunology"},{"issue":"4","key":"11156_CR15","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1097\/MS9.0000000000003002","volume":"87","author":"E Zare","year":"2025","unstructured":"Zare, E., Mostafavi, S. M., Norouzi, N., Larijani, A., Mosavi Mirkalaie, S. M., FallahMortezaNejad, S. A., Jafari, M., Shahabinejad, E., Lasboo, A., M., & Anvari, S. (2025). Exploring the potential of CAR-NK cell therapy in the management of head and neck cancer (Hnc): A narrative review. Annals of Medicine & Surgery, 87(4), 2026\u20132034. https:\/\/doi.org\/10.1097\/MS9.0000000000003002","journal-title":"Annals of Medicine & Surgery"},{"key":"11156_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1574742","volume":"16","author":"S Balkhi","year":"2025","unstructured":"Balkhi, S., Zuccolotto, G., Di Spirito, A., Rosato, A., & Mortara, L. (2025). CAR-NK cell therapy: Promise and challenges in solid tumors. Frontiers in Immunology, 16, Article 1574742. https:\/\/doi.org\/10.3389\/fimmu.2025.1574742","journal-title":"Frontiers in Immunology"},{"key":"11156_CR17","doi-asserted-by":"publisher","first-page":"834002","DOI":"10.3389\/fonc.2022.834002","volume":"12","author":"E Elmas","year":"2022","unstructured":"Elmas, E., Saljoughian, N., De Souza Fernandes Pereira, M., Tullius, B. P., Sorathia, K., Nakkula, R. J., Lee, D. A., & Kararoudi, N., M (2022). Crispr gene editing of human primary nk and t cells for cancer immunotherapy. Frontiers in Oncology, 12, 834002. https:\/\/doi.org\/10.3389\/fonc.2022.834002","journal-title":"Frontiers in Oncology"},{"issue":"10","key":"11156_CR18","doi-asserted-by":"publisher","first-page":"e20220830","DOI":"10.1084\/jem.20220830","volume":"219","author":"L Chiossone","year":"2022","unstructured":"Chiossone, L., & Vivier, E. (2022). Bringing natural killer cells to the clinic. Journal of Experimental Medicine, 219(10), e20220830. https:\/\/doi.org\/10.1084\/jem.20220830","journal-title":"Journal of Experimental Medicine"},{"key":"11156_CR19","doi-asserted-by":"publisher","first-page":"732135","DOI":"10.3389\/fimmu.2021.732135","volume":"12","author":"EL Heipertz","year":"2021","unstructured":"Heipertz, E. L., Zynda, E. R., Stav-Noraas, T. E., Hungler, A. D., Boucher, S. E., Kaur, N., & Vemuri, M. C. (2021). Current perspectives on off-the-shelf allogeneic nk and car-nk cell therapies. Frontiers in Immunology, 12, 732135. https:\/\/doi.org\/10.3389\/fimmu.2021.732135","journal-title":"Frontiers in Immunology"},{"issue":"4","key":"11156_CR20","doi-asserted-by":"publisher","first-page":"e1115178","DOI":"10.1080\/2162402X.2015.1115178","volume":"5","author":"U Koehl","year":"2016","unstructured":"Koehl, U., Kalberer, C., Spanholtz, J., Lee, D. A., Miller, J. S., Cooley, S., Lowdell, M., Uharek, L., Klingemann, H., Curti, A., Leung, W., & Alici, E. (2016). Advances in clinical NK cell studies: Donor selection, manufacturing and quality control. OncoImmunology, 5(4), e1115178. https:\/\/doi.org\/10.1080\/2162402X.2015.1115178","journal-title":"OncoImmunology"},{"key":"11156_CR21","doi-asserted-by":"publisher","first-page":"1412378","DOI":"10.3389\/fimmu.2024.1412378","volume":"15","author":"X Wang","year":"2024","unstructured":"Wang, X., Byrne, M. E., Liu, C., Ma, M. T., & Liu, D. (2024). Scalable process development of NK and CAR-NK expansion in a closed bioreactor. Frontiers in Immunology, 15, 1412378. https:\/\/doi.org\/10.3389\/fimmu.2024.1412378","journal-title":"Frontiers in Immunology"},{"issue":"4","key":"11156_CR22","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s00262-015-1761-x","volume":"65","author":"G Suck","year":"2016","unstructured":"Suck, G., Odendahl, M., Nowakowska, P., Seidl, C., Wels, W. S., Klingemann, H. G., & Tonn, T. (2016). NK-92: An \u2018off-the-shelf therapeutic\u2019 for adoptive natural killer cell-based cancer immunotherapy. Cancer Immunology Immunotherapy, 65(4), 485\u2013492. https:\/\/doi.org\/10.1007\/s00262-015-1761-x","journal-title":"Cancer Immunology Immunotherapy"},{"key":"11156_CR23","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.reth.2025.07.014","volume":"30","author":"T Kikuchi","year":"2025","unstructured":"Kikuchi, T., Takeuchi, I., & Yamaguchi, H. (2025). Scalable production process development for NK cells targeting large-scale expansion. Regenerative Therapy, 30, 535\u2013543. https:\/\/doi.org\/10.1016\/j.reth.2025.07.014","journal-title":"Regenerative Therapy"},{"key":"11156_CR24","doi-asserted-by":"publisher","first-page":"890894","DOI":"10.3389\/fimmu.2022.890894","volume":"13","author":"N Boyd-Gibbins","year":"2022","unstructured":"Boyd-Gibbins, N., Karagiannis, P., Hwang, D. W., & Kim, S. I. (2022). Ipscs in nk cell manufacturing and nkev development. Frontiers in Immunology, 13, 890894. https:\/\/doi.org\/10.3389\/fimmu.2022.890894","journal-title":"Frontiers in Immunology"},{"issue":"2","key":"11156_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/mmr.2025.13587","volume":"32","author":"X Wei","year":"2025","unstructured":"Wei, X., Su, C., Liu, Y., Wei, N., Xiang, K., Qian, Q., & Xu, Z. (2025). IPSC-derived NK cells for immunotherapy and therapeutic perspective (review). Molecular Medicine Reports, 32(2), 1\u201315. https:\/\/doi.org\/10.3892\/mmr.2025.13587","journal-title":"Molecular Medicine Reports"},{"issue":"2","key":"11156_CR26","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/imm.13094","volume":"158","author":"LO Afolabi","year":"2019","unstructured":"Afolabi, L. O., Adeshakin, A. O., Sani, M. M., Bi, J., & Wan, X. (2019). Genetic reprogramming for NK cell cancer immunotherapy with CRISPR\/Cas9. Immunology, 158(2), 63\u201369. https:\/\/doi.org\/10.1111\/imm.13094","journal-title":"Immunology"},{"key":"11156_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2021.104436","volume":"369","author":"L Zhi","year":"2021","unstructured":"Zhi, L., Su, X., Yin, M., Zhang, Z., Lu, H., Niu, Z., Guo, C., Zhu, W., & Zhang, X. (2021). Genetical engineering for NK and T cell immunotherapy with CRISPR\/Cas9 technology: Implications and challenges. Cellular Immunology, 369, Article 104436. https:\/\/doi.org\/10.1016\/j.cellimm.2021.104436","journal-title":"Cellular Immunology"},{"key":"11156_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.607131","volume":"11","author":"S Mantesso","year":"2020","unstructured":"Mantesso, S., Geerts, D., Spanholtz, J., & Ku\u010derov\u00e1, L. (2020). Genetic engineering of natural killer cells for enhanced antitumor function. Frontiers in Immunology, 11, Article 607131. https:\/\/doi.org\/10.3389\/fimmu.2020.607131","journal-title":"Frontiers in Immunology"},{"issue":"11","key":"11156_CR29","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1016\/j.ccell.2025.09.013","volume":"43","author":"A Biederst\u00e4dt","year":"2025","unstructured":"Biederst\u00e4dt, A., & Rezvani, K. (2025). Engineered natural killer cells for cancer therapy. Cancer Cell, 43(11), 1987\u20132013. https:\/\/doi.org\/10.1016\/j.ccell.2025.09.013","journal-title":"Cancer Cell"},{"issue":"3","key":"11156_CR30","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1093\/stcltm\/szad087","volume":"13","author":"A Maia","year":"2024","unstructured":"Maia, A., Tarannum, M., & Romee, R. (2024). Genetic manipulation approaches to enhance the clinical application of NK cell-based immunotherapy. Stem Cells Translational Medicine, 13(3), 230\u2013242. https:\/\/doi.org\/10.1093\/stcltm\/szad087","journal-title":"Stem Cells Translational Medicine"},{"key":"11156_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1600411","volume":"16","author":"C Hu","year":"2025","unstructured":"Hu, C., Lai, W., Tian, B., Xu, X., Xie, S., Zhong, W., Kang, H., Chen, X., Li, H., Xu, J., & Liu, L. (2025). Application and prospects of genetic engineering in CAR-NK cell therapy. Frontiers in Immunology, 16, Article 1600411. https:\/\/doi.org\/10.3389\/fimmu.2025.1600411","journal-title":"Frontiers in Immunology"},{"issue":"2","key":"11156_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010763","volume":"13","author":"R Rahnama","year":"2025","unstructured":"Rahnama, R., Kizerwetter, M., Yang, H., Christodoulou, I., Guaraca, C., Holl, N. J., Choe, J., Vorri, S. C., Zinsky, M., Jones, D. G., Garcia Espinoza, N., Kuo, Y. H., Zahurak, M., Varadhan, R., Spangler, J. B., & Bonifant, C. L. (2025). Single-chain variable fragment affinity tuning can optimize anti-AML CAR-NK cell functionality. Journal for ImmunoTherapy of Cancer, 13(2), Article e010763. https:\/\/doi.org\/10.1136\/jitc-2024-010763","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"11156_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.822298","volume":"13","author":"KE Ruppel","year":"2022","unstructured":"Ruppel, K. E., Fricke, S., K\u00f6hl, U., & Schmiedel, D. (2022). Taking lessons from car-t cells and going beyond: Tailoring design and signaling for car-nk cells in cancer therapy. Frontiers in Immunology, 13, Article 822298. https:\/\/doi.org\/10.3389\/fimmu.2022.822298","journal-title":"Frontiers in Immunology"},{"key":"11156_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1674376","volume":"16","author":"S Jo","year":"2025","unstructured":"Jo, S., Lee, Y. B., Kim, S. M., Lee, S. Y., Choi, M., Kyun, M., Jeong, S. Y., Lee, S., Kim, J. H., Kim, Y., Kim, Y. J., Park, S., Moon, K. S., & Kim, T. D. (2025). Fine-tuning signal strength in CD5 CAR-NK cells for targeted T cell cancer therapy. Frontiers in Immunology, 16, Article 1674376. https:\/\/doi.org\/10.3389\/fimmu.2025.1674376","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"11156_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-76791-2","volume":"14","author":"F Jahan","year":"2024","unstructured":"Jahan, F., Penna, L., Luostarinen, A., Veltman, L., Hongisto, H., L\u00e4hteenm\u00e4ki, K., M\u00fcller, S., Yl\u00e4-Herttuala, S., Korhonen, M., Vettenranta, K., Laitinen, A., Salmenniemi, U., & Kerkel\u00e4, E. (2024). Automated and closed clinical-grade manufacturing protocol produces potent NK cells against neuroblastoma cells and AML blasts. Scientific Reports, 14(1), Article 26678. https:\/\/doi.org\/10.1038\/s41598-024-76791-2","journal-title":"Scientific Reports"},{"issue":"5","key":"11156_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004693","volume":"10","author":"S Maddineni","year":"2022","unstructured":"Maddineni, S., Silberstein, J. L., & Sunwoo, J. B. (2022). Emerging NK cell therapies for cancer and the promise of next generation engineering of iPSC-derived NK cells. Journal for ImmunoTherapy of Cancer, 10(5), Article e004693. https:\/\/doi.org\/10.1136\/jitc-2022-004693","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"11156_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1491282","volume":"12","author":"M Alidadi","year":"2024","unstructured":"Alidadi, M., Barzgar, H., Zaman, M., Paevskaya, O. A., Metanat, Y., Khodabandehloo, E., & Moradi, V. (2024). Combining the induced pluripotent stem cell (Ipsc) technology with chimeric antigen receptor (Car)-based immunotherapy: Recent advances, challenges, and future prospects. Frontiers in Cell and Developmental Biology, 12, Article 1491282. https:\/\/doi.org\/10.3389\/fcell.2024.1491282","journal-title":"Frontiers in Cell and Developmental Biology"},{"key":"11156_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.841107","volume":"13","author":"BH Goldenson","year":"2022","unstructured":"Goldenson, B. H., Hor, P., & Kaufman, D. S. (2022). Ipsc-derived natural killer cell therapies\u2014Expansion and targeting. Frontiers in Immunology, 13, Article 841107. https:\/\/doi.org\/10.3389\/fimmu.2022.841107","journal-title":"Frontiers in Immunology"},{"issue":"8","key":"11156_CR39","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1182\/blood.2022016205","volume":"141","author":"F Cichocki","year":"2023","unstructured":"Cichocki, F., Van Der Stegen, S. J. C., & Miller, J. S. (2023). Engineered and banked iPSCs for advanced NK- and T-cell immunotherapies. Blood, 141(8), 846\u2013855. https:\/\/doi.org\/10.1182\/blood.2022016205","journal-title":"Blood"},{"key":"11156_CR40","doi-asserted-by":"publisher","first-page":"4273","DOI":"10.2147\/OTT.S139986","volume":"1","author":"S Liang","year":"2017","unstructured":"Liang, S., Xu, K., Niu, L., Wang, X., Liang, Y., Zhang, M., Chen, J., & Lin, M. (2017). Comparison of autogeneic and allogeneic natural killer cells immunotherapy on the clinical outcome of recurrent breast cancer. Onco Targets and Therapy, 1, 4273\u20134281. https:\/\/doi.org\/10.2147\/OTT.S139986","journal-title":"Onco Targets and Therapy"},{"key":"11156_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1595533","volume":"16","author":"M Chen","year":"2025","unstructured":"Chen, M., Zhang, B., Mu, X., Zhang, B., Yang, T., Zhang, G., Gu, Y., Pei, B., & Liang, S. (2025). Recent advances in tumor immunotherapy based on NK cells. Frontiers in Immunology, 16, Article 1595533. https:\/\/doi.org\/10.3389\/fimmu.2025.1595533","journal-title":"Frontiers in Immunology"},{"issue":"2","key":"11156_CR42","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s00262-016-1882-x","volume":"66","author":"R Tarazona","year":"2017","unstructured":"Tarazona, R., Sanchez-Correa, B., Casas-Avil\u00e9s, I., Campos, C., Pera, A., Morgado, S., L\u00f3pez-Sejas, N., Hassouneh, F., Bergua, J. M., Arcos, M. J., Ba\u00f1as, H., Casado, J. G., Dur\u00e1n, E., Labella, F., & Solana, R. (2017). Immunosenescence: Limitations of natural killer cell-based cancer immunotherapy. Cancer Immunology Immunotherapy, 66(2), 233\u2013245. https:\/\/doi.org\/10.1007\/s00262-016-1882-x","journal-title":"Cancer Immunology Immunotherapy"},{"issue":"11","key":"11156_CR43","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/j.jcyt.2014.03.009","volume":"16","author":"JOJ Davies","year":"2014","unstructured":"Davies, J. O. J., Stringaris, K., Barrett, A. J., & Rezvani, K. (2014). Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease. Cytotherapy, 16(11), 1453\u20131466. https:\/\/doi.org\/10.1016\/j.jcyt.2014.03.009","journal-title":"Cytotherapy"},{"issue":"7","key":"11156_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.70045","volume":"14","author":"J Sun","year":"2025","unstructured":"Sun, J., Elliott, M., & Souza-Fonseca-Guimaraes, F. (2025). Engineered iPSC-derived natural killer cells: Recent innovations in translational innate anti-cancer immunotherapy. Clinical & Translational Immunology, 14(7), Article e70045. https:\/\/doi.org\/10.1002\/cti2.70045","journal-title":"Clinical & Translational Immunology"},{"key":"11156_CR45","doi-asserted-by":"publisher","unstructured":"Sarvaria, A., Jawdat, D., Madrigal, J. A., & Saudemont, A. (2017). Umbilical cord blood natural killer cells, their characteristics, and potential clinical applications. Frontiers in Immunology, 8. https:\/\/doi.org\/10.3389\/fimmu.2017.00329","DOI":"10.3389\/fimmu.2017.00329"},{"key":"11156_CR46","doi-asserted-by":"publisher","unstructured":"Mehta, R. S., Shpall, E. J., & Rezvani, K. (2016). Cord blood as a source of natural killer cells. Frontiers in Medicine, 2. https:\/\/doi.org\/10.3389\/fmed.2015.00093","DOI":"10.3389\/fmed.2015.00093"},{"issue":"2","key":"11156_CR47","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/j.1365-2141.2009.07768.x","volume":"147","author":"MR Verneris","year":"2009","unstructured":"Verneris, M. R., & Miller, J. S. (2009). The phenotypic and functional characteristics of umbilical cord blood and peripheral blood natural killer cells. British Journal of Haematology, 147(2), 185\u2013191. https:\/\/doi.org\/10.1111\/j.1365-2141.2009.07768.x","journal-title":"British Journal of Haematology"},{"key":"11156_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.584099","volume":"11","author":"X Zhao","year":"2020","unstructured":"Zhao, X., Cai, L., Hu, Y., & Wang, H. (2020). Cord-blood natural killer cell-based immunotherapy for cancer. Frontiers in Immunology, 11, Article 584099. https:\/\/doi.org\/10.3389\/fimmu.2020.584099","journal-title":"Frontiers in Immunology"},{"key":"11156_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1167266","volume":"13","author":"J Wang","year":"2023","unstructured":"Wang, J., & Metheny, L. (2023). Umbilical cord blood derived cellular therapy: Advances in clinical development. Frontiers in Oncology, 13, Article 1167266. https:\/\/doi.org\/10.3389\/fonc.2023.1167266","journal-title":"Frontiers in Oncology"},{"issue":"3","key":"11156_CR50","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41591-023-02785-8","volume":"30","author":"D Marin","year":"2024","unstructured":"Marin, D., Basar, R., Pahl, M., Kerbauy, L. N., Lapteva, N., Ghungroo, A., et al. (2024). Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19\u2009+\u2009B cell tumors: A phase 1\/2 trial. Nature Medicine, 30(3), 772\u2013784. https:\/\/doi.org\/10.1038\/s41591-023-02785-8","journal-title":"Nature Medicine"},{"issue":"4","key":"11156_CR51","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1182\/blood.V100.4.1265","volume":"100","author":"C Uherek","year":"2002","unstructured":"Uherek, C., Tonn, T., Uherek, B., Becker, S., Schnierle, B., Klingemann, H. G., et al. (2002). Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction. Blood, 100(4), 1265\u20131273. https:\/\/doi.org\/10.1182\/blood.V100.4.1265","journal-title":"Blood"},{"issue":"12","key":"11156_CR52","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/j.jcyt.2013.06.017","volume":"15","author":"T Tonn","year":"2013","unstructured":"Tonn, T., Schwabe, D., Klingemann, H. G., Becker, S., Esser, R., Koehl, U., et al. (2013). Treatment of patients with advanced cancer with the natural killer cell line NK-92. Cytotherapy, 15(12), 1563\u20131570. https:\/\/doi.org\/10.1016\/j.jcyt.2013.06.017","journal-title":"Cytotherapy"},{"issue":"51","key":"11156_CR53","doi-asserted-by":"publisher","first-page":"89256","DOI":"10.18632\/oncotarget.19204","volume":"8","author":"BA Williams","year":"2017","unstructured":"Williams, B. A., Law, A. D., Routy, B., den Hollander, N., Gupta, V., Wang, X. H., Chaboureau, A., Viswanathan, S., & Keating, A. (2017). A Phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy. Oncotarget, 8(51), 89256\u201389268. https:\/\/doi.org\/10.18632\/oncotarget.19204","journal-title":"Oncotarget"},{"issue":"11","key":"11156_CR54","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1093\/neuonc\/noad087","volume":"25","author":"MC Burger","year":"2023","unstructured":"Burger, M. C., Forster, M. T., Romanski, A., Stra\u00dfheimer, F., Macas, J., Zeiner, P. S., et al. (2023). Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma. Neuro-Oncology, 25(11), 2058\u20132071. https:\/\/doi.org\/10.1093\/neuonc\/noad087","journal-title":"Neuro-Oncology"},{"key":"11156_CR55","unstructured":"ClinicalTrials.gov. (2022). Study for subjects with relapsed\/refractory B-cell non-Hodgkin lymphoma (NCT05618925). U.S. National Library of Medicine. Retrieved April 21, 2026, from https:\/\/clinicaltrials.gov\/study\/NCT05618925"},{"key":"11156_CR56","unstructured":"ClinicalTrials.gov. (2017). QUILT-3.044: NANT non-small cell lung cancer vaccine (NCT03169738). U.S. National Library of Medicine. Retrieved April 21, 2026, from https:\/\/clinicaltrials.gov\/study\/NCT03169738"},{"key":"11156_CR57","unstructured":"ClinicalTrials.gov. (2017). QUILT-3.060: NANT pancreatic cancer vaccine (NCT03329248). U.S. National Library of Medicine. Retrieved April 21, 2026, from https:\/\/clinicaltrials.gov\/study\/NCT03329248"},{"key":"11156_CR58","doi-asserted-by":"publisher","unstructured":"Klingemann, H., Boissel, L., & Toneguzzo, F. (2016). Natural killer cells for immunotherapy \u2013 advantages of the nk-92 cell line over blood nk cells. Frontiers in Immunology, 7. https:\/\/doi.org\/10.3389\/fimmu.2016.00091","DOI":"10.3389\/fimmu.2016.00091"},{"issue":"12","key":"11156_CR59","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.3390\/cancers17121968","volume":"17","author":"H Klingemann","year":"2025","unstructured":"Klingemann, H. (2025). The natural killer cell line NK-92 and its genetic variants: Impact on NK cell research and cancer immunotherapy. Cancers, 17(12), 1968. https:\/\/doi.org\/10.3390\/cancers17121968","journal-title":"Cancers"},{"issue":"1","key":"11156_CR60","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2025.2559782","volume":"14","author":"D Giraldos","year":"2025","unstructured":"Giraldos, D., Galano-Frutos, E., Cambronero-Arregui, L., Beltr\u00e1n Visiedo, M., Romanos, E., Reina-Ortiz, C., Azaceta, G., Mart\u00ednez-L\u00e1zaro, B., Men\u00e9ndez-J\u00e1ndula, B., Garc\u00eda-Romero, A., Jim\u00e9nez-Albericio, F. J., Marzo, I., Naval, J., & Anel, A. (2025). NK92 cells stably transfected with CD16 are efficient against multiple myeloma cells ex vivo and in vivo, especially if combined with daratumumab. OncoImmunology, 14(1), Article 2559782. https:\/\/doi.org\/10.1080\/2162402X.2025.2559782","journal-title":"OncoImmunology"},{"issue":"7","key":"11156_CR61","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/j.cell.2019.05.043","volume":"177","author":"D Crow","year":"2019","unstructured":"Crow, D. (2019). Could iPSCs enable off-the-shelf cell therapy? Cell, 177(7), 1667\u20131669. https:\/\/doi.org\/10.1016\/j.cell.2019.05.043","journal-title":"Cell"},{"issue":"S2","key":"11156_CR62","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1002\/sctm.21-0135","volume":"10","author":"SJ Lu","year":"2021","unstructured":"Lu, S. J., & Feng, Q. (2021). CAR-NK cells from engineered pluripotent stem cells: Off-the-shelf therapeutics for all patients. Stem Cells Translational Medicine, 10(S2), S10\u2013S17. https:\/\/doi.org\/10.1002\/sctm.21-0135","journal-title":"Stem Cells Translational Medicine"},{"key":"11156_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1463736","volume":"15","author":"M Huyghe","year":"2024","unstructured":"Huyghe, M., Desterke, C., Imeri, J., Belliard, N., Chaker, D., Oudrirhi, N., Bezerra, H., Turhan, A. G., Bennaceur-Griscelli, A., & Griscelli, F. (2024). Comparative analysis of iPSC-derived NK cells from two differentiation strategies reveals distinct signatures and cytotoxic activities. Frontiers in Immunology, 15, Article 1463736. https:\/\/doi.org\/10.3389\/fimmu.2024.1463736","journal-title":"Frontiers in Immunology"},{"issue":"10","key":"11156_CR64","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.jcyt.2021.05.001","volume":"23","author":"KB Lupo","year":"2021","unstructured":"Lupo, K. B., Moon, J. I., Chambers, A. M., & Matosevic, S. (2021). Differentiation of natural killer cells from induced pluripotent stem cells under defined, serum- and feeder-free conditions. Cytotherapy, 23(10), 939\u2013952. https:\/\/doi.org\/10.1016\/j.jcyt.2021.05.001","journal-title":"Cytotherapy"},{"issue":"8","key":"11156_CR65","doi-asserted-by":"publisher","first-page":"541","DOI":"10.14348\/molcells.2021.0078","volume":"44","author":"P Karagiannis","year":"2021","unstructured":"Karagiannis, P., & Kim, S. I. (2021). IPSC-derived natural killer cells for cancer immunotherapy. Molecules and Cells, 44(8), 541\u2013548. https:\/\/doi.org\/10.14348\/molcells.2021.0078","journal-title":"Molecules and Cells"},{"issue":"6","key":"11156_CR66","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1016\/j.stemcr.2017.10.020","volume":"9","author":"J Zeng","year":"2017","unstructured":"Zeng, J., Tang, S. Y., Toh, L. L., & Wang, S. (2017). Generation of off-the-shelf natural killer cells from peripheral blood cell-derived induced pluripotent stem cells. Stem Cell Reports, 9(6), 1796\u20131812. https:\/\/doi.org\/10.1016\/j.stemcr.2017.10.020","journal-title":"Stem Cell Reports"},{"issue":"4","key":"11156_CR67","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.13425","volume":"56","author":"C Wang","year":"2023","unstructured":"Wang, C., Liu, J., & Li, W. (2023). Off the shelf\u2019 immunotherapies: Generation and application of pluripotent stem cell-derived immune cells. Cell Proliferation, 56(4), Article e13425. https:\/\/doi.org\/10.1111\/cpr.13425","journal-title":"Cell Proliferation"},{"key":"11156_CR68","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.bioactmat.2024.02.031","volume":"36","author":"S Kiran","year":"2024","unstructured":"Kiran, S., Xue, Y., Sarker, D. B., Li, Y., & Sang, Q. X. A. (2024). Feeder-free differentiation of human iPSCs into natural killer cells with cytotoxic potential against malignant brain rhabdoid tumor cells. Bioactive Materials, 36, 301\u2013316. https:\/\/doi.org\/10.1016\/j.bioactmat.2024.02.031","journal-title":"Bioactive Materials"},{"key":"11156_CR69","doi-asserted-by":"publisher","unstructured":"Zhu, H., & Kaufman, D. S. (2019). An improved method to produce clinical-scale natural killer cells from human pluripotent stem cells. In S. Kaneko (Ed.), In Vitro Differentiation of T-Cells (Vol. Vol. 2048, pp. 107\u2013119). Springer. https:\/\/doi.org\/10.1007\/978-1-4939-9728-2_12","DOI":"10.1007\/978-1-4939-9728-2_12"},{"key":"11156_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.640672","volume":"12","author":"J Euchner","year":"2021","unstructured":"Euchner, J., Sprissler, J., Cathomen, T., F\u00fcrst, D., Schrezenmeier, H., Debatin, K. M., Schwarz, K., & Felgentreff, K. (2021). Natural killer cells generated from human induced pluripotent stem cells mature to CD56brightCD16\u2009+\u2009NKP80+\/-in-vitro and express KIR2DL2\/DL3 and KIR3DL1. Frontiers in Immunology, 12, Article 640672. https:\/\/doi.org\/10.3389\/fimmu.2021.640672","journal-title":"Frontiers in Immunology"},{"key":"11156_CR71","unstructured":"Creation of embryoid bodies from human ipscs & mouse escs\u2014Us. (n.d.). Retrieved March 24, (2026). from https:\/\/www.thermofisher.com\/us\/en\/home\/references\/protocols\/cell-culture\/stem-cell-protocols\/ipsc-protocols\/embryoid-bodies-from-ipscs.html"},{"issue":"2","key":"11156_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/mmr.2025.13587","volume":"32","author":"X Wei","year":"2025","unstructured":"Wei, X., Su, C., Liu, Y., Wei, N., Xiang, K., Qian, Q., & Xu, Z. (2025). IPSC-derived NK cells for immunotherapy and therapeutic perspective (Review). Molecular Medicine Reports, 32(2), 1\u201315. https:\/\/doi.org\/10.3892\/mmr.2025.13587","journal-title":"Molecular Medicine Reports"},{"issue":"10","key":"11156_CR73","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","volume":"22","author":"TJ Laskowski","year":"2022","unstructured":"Laskowski, T. J., Biederst\u00e4dt, A., & Rezvani, K. (2022). Natural killer cells in antitumour adoptive cell immunotherapy. Nature Reviews Cancer, 22(10), 557\u2013575. https:\/\/doi.org\/10.1038\/s41568-022-00491-0","journal-title":"Nature Reviews Cancer"},{"key":"11156_CR74","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2025.1627149","volume":"13","author":"S Dhaiban","year":"2025","unstructured":"Dhaiban, S., Chandran, S., Noshi, M., & Sajini, A. A. (2025). Clinical translation of human iPSC technologies: Advances, safety concerns, and future directions. Frontiers in Cell and Developmental Biology, 13, Article 1627149. https:\/\/doi.org\/10.3389\/fcell.2025.1627149","journal-title":"Frontiers in Cell and Developmental Biology"},{"issue":"1","key":"11156_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52388-1","volume":"15","author":"T Bexte","year":"2024","unstructured":"Bexte, T., Albinger, N., Al Ajami, A., Wendel, P., Buchinger, L., Gessner, A., Alzubi, J., S\u00e4rchen, V., Vogler, M., Rasheed, H. M., Jung, B. A., Wolf, S., Bhayadia, R., Oellerich, T., Klusmann, J.-H., Penack, O., M\u00f6ker, N., Cathomen, T., Rieger, M. A., \u2026 Ullrich, E. (2024). CRISPR\/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells. Nature Communications, 15(1), Article 8439. https:\/\/doi.org\/10.1038\/s41467-024-52388-1","journal-title":"Nature Communications"},{"issue":"11","key":"11156_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102282","volume":"6","author":"A Kumar","year":"2025","unstructured":"Kumar, A., Fischer, C., Cichocki, F., & Miller, J. S. (2025). Multiplexed iPSC platform for advanced NK cell immunotherapies. Cell Reports Medicine, 6(11), Article 102282. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102282","journal-title":"Cell Reports Medicine"},{"key":"11156_CR77","doi-asserted-by":"publisher","unstructured":"Zong, H., & Wang, R. (2025). Gmp manufacturing of allogenic ipsc-nk cells for immunotherapy. In G. N. Stacey & T. Zhao (Eds.), Cell Therapy Manufacturing (Vol. 1486, pp. 179\u2013192). Springer Nature Switzerland. https:\/\/doi.org\/10.1007\/978-3-031-97297-3_15","DOI":"10.1007\/978-3-031-97297-3_15"},{"key":"11156_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2025.115744","volume":"229","author":"A Haase","year":"2026","unstructured":"Haase, A., Ruhparwar, A., & Martin, U. (2026). GMP-compliant manufacturing of iPSC-derived therapeutic cell products: Technologies, applications, risks and limitations. Advanced Drug Delivery Reviews, 229, Article 115744. https:\/\/doi.org\/10.1016\/j.addr.2025.115744","journal-title":"Advanced Drug Delivery Reviews"},{"key":"11156_CR79","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2025.1716975","volume":"13","author":"V Von Werz","year":"2025","unstructured":"Von Werz, V., Szarzynski, A., Zigon-Branc, S., & Spadiut, O. (2025). Quality standards for NK cell immunotherapies. Frontiers in Bioengineering and Biotechnology, 13, Article 1716975. https:\/\/doi.org\/10.3389\/fbioe.2025.1716975","journal-title":"Frontiers in Bioengineering and Biotechnology"},{"key":"11156_CR80","unstructured":"Huang, J., & Ramping Up GMP-Compliant, C. A. R. N. K. (2025). Manufacturing At Scale With iPSCs. cell gene. Retrieved April 15, from https:\/\/www.cellandgene.com\/doc\/ramping-up-gmp-compliant-car-nk-manufacturing-at-scale-with-ipscs-0001.html"},{"issue":"11","key":"11156_CR81","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1093\/stmcls\/sxad059","volume":"41","author":"S Alasmar","year":"2023","unstructured":"Alasmar, S., Huang, J., Chopra, K., Baumann, E., Aylsworth, A., Hewitt, M., Sandhu, J. K., Tauskela, J. S., Ben, R. N., & Jezierski, A. (2023). Improved cryopreservation of human induced pluripotent stem cell (Ipsc) and ipsc-derived neurons using ice-recrystallization inhibitors. Stem Cells, 41(11), 1006\u20131021. https:\/\/doi.org\/10.1093\/stmcls\/sxad059","journal-title":"Stem Cells"},{"issue":"1","key":"11156_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47574-0","volume":"15","author":"A Berjis","year":"2024","unstructured":"Berjis, A., Muthumani, D., Aguilar, O. A., Pomp, O., Johnson, O., Finck, A. V., Engel, N. W., Chen, L., Plachta, N., Scholler, J., Lanier, L. L., June, C. H., & Sheppard, N. C. (2024). Pretreatment with IL-15 and IL-18 rescues natural killer cells from granzyme B-mediated apoptosis after cryopreservation. Nature Communications, 15(1), Article 3937. https:\/\/doi.org\/10.1038\/s41467-024-47574-0","journal-title":"Nature Communications"},{"key":"11156_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1304689","volume":"14","author":"JN Saultz","year":"2023","unstructured":"Saultz, J. N., & Otegbeye, F. (2023). Optimizing the cryopreservation and post-thaw recovery of natural killer cells is critical for the success of off-the-shelf platforms. Frontiers in Immunology, 14, Article 1304689. https:\/\/doi.org\/10.3389\/fimmu.2023.1304689","journal-title":"Frontiers in Immunology"},{"key":"11156_CR84","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1304689","volume":"14","author":"JN Saultz","year":"2023","unstructured":"Saultz, J. N., & Otegbeye, F. (2023). Optimizing the cryopreservation and post-thaw recovery of natural killer cells is critical for the success of off-the-shelf platforms. Frontiers in Immunology, 14, Article 1304689. https:\/\/doi.org\/10.3389\/fimmu.2023.1304689","journal-title":"Frontiers in Immunology"},{"issue":"4","key":"11156_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2024.200885","volume":"32","author":"D Kwon","year":"2024","unstructured":"Kwon, D., Moon, B. K., Han, M., Lee, T. W., Lee, J., & Kang, K. S. (2024). Genetically stable multi-gene edited iPSCs-derived NK cells for enhanced cancer immunotherapy. Molecular Therapy: Oncology, 32(4), Article 200885. https:\/\/doi.org\/10.1016\/j.omton.2024.200885","journal-title":"Molecular Therapy: Oncology"},{"key":"11156_CR86","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2023.1143157","volume":"11","author":"C Guo","year":"2023","unstructured":"Guo, C., Ma, X., Gao, F., & Guo, Y. (2023). Off-target effects in CRISPR\/Cas9 gene editing. Frontiers in Bioengineering and Biotechnology, 11, Article 1143157. https:\/\/doi.org\/10.3389\/fbioe.2023.1143157","journal-title":"Frontiers in Bioengineering and Biotechnology"},{"key":"11156_CR87","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2023.1339189","volume":"11","author":"R Lopes","year":"2024","unstructured":"Lopes, R., & Prasad, M. K. (2024). Beyond the promise: Evaluating and mitigating off-target effects in CRISPR gene editing for safer therapeutics. Frontiers in Bioengineering and Biotechnology, 11, Article 1339189. https:\/\/doi.org\/10.3389\/fbioe.2023.1339189","journal-title":"Frontiers in Bioengineering and Biotechnology"},{"key":"11156_CR88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1711414","volume":"16","author":"A Fazeli","year":"2025","unstructured":"Fazeli, A., Ullrich, E., Cathomen, T., & Bexte, T. (2025). Engineering with care: Safety assessment platforms for CRISPR-modified natural killer cells. Frontiers in Immunology, 16, Article 1711414. https:\/\/doi.org\/10.3389\/fimmu.2025.1711414","journal-title":"Frontiers in Immunology"},{"issue":"Supplement 1","key":"11156_CR89","doi-asserted-by":"publisher","first-page":"5913","DOI":"10.1182\/blood-2025-5913","volume":"146","author":"JL Thangaraj","year":"2025","unstructured":"Thangaraj, J. L., Lopez, E., Tharp, K., & Kaufman, D. (2025). Engineered iPSC-derived NK cells targeting the SIGLEC7-glyco-immune checkpoint improves anti-tumor activity in solid cancers. Blood, 146(Supplement 1), 5913\u20135913. https:\/\/doi.org\/10.1182\/blood-2025-5913","journal-title":"Blood"},{"issue":"7","key":"11156_CR90","doi-asserted-by":"publisher","first-page":"e505","DOI":"10.1016\/S2352-3026(25)00142-5","volume":"12","author":"P Strati","year":"2025","unstructured":"Strati, P., Castro, J., Goodman, A., Bachanova, V., Kamdar, M., Awan, F. T., Solomon, S. R., Wong, L., Wong, C., Patel, D., Bickers, C., Zhao, W., Bashir, Z., Valamehr, B., Elstrom, R. L., & Patel, K. (2025). Off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy in relapsed or refractory B-cell lymphoma: A multicentre, open-label, phase 1 study. The Lancet Haematology, 12(7), e505\u2013e515. https:\/\/doi.org\/10.1016\/S2352-3026(25)00142-5","journal-title":"The Lancet Haematology"},{"issue":"1","key":"11156_CR91","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s13046-025-03558-6","volume":"44","author":"N Romanini","year":"2025","unstructured":"Romanini, N., Netsrithong, R., Themeli, M., & Tazzari, M. (2025). Challenges and opportunities of human iPSC-derived NK as off-the-shelf cellular therapies. Journal of Experimental & Clinical Cancer Research, 44(1), 327. https:\/\/doi.org\/10.1186\/s13046-025-03558-6","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"issue":"10473","key":"11156_CR92","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0140-6736(24)02462-0","volume":"405","author":"A Ghobadi","year":"2025","unstructured":"Ghobadi, A., Bachanova, V., Patel, K., Park, J. H., Flinn, I., Riedell, P. A., Bachier, C., Diefenbach, C. S., Wong, C., Bickers, C., Wong, L., Patel, D., Goodridge, J., Denholt, M., Valamehr, B., Elstrom, R. L., & Strati, P. (2025). Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in b-cell lymphoma: A phase 1, first-in-human trial. The Lancet, 405(10473), 127\u2013136. https:\/\/doi.org\/10.1016\/S0140-6736(24)02462-0","journal-title":"The Lancet"},{"key":"11156_CR93","unstructured":"ClinicalTrials.gov. (2019). FT500 as monotherapy and in combination with immune checkpoint inhibitors in subjects with advanced solid tumors (NCT03841110). U.S. National Library of Medicine. Retrieved April 21, 2026, from https:\/\/clinicaltrials.gov\/study\/NCT03841110"},{"key":"11156_CR94","unstructured":"ClinicalTrials.gov. (2020). FT516 and IL2 with enoblituzumab for ovarian cancer (NCT04630769). U.S. National Library of Medicine. Retrieved April 21, 2026, from https:\/\/clinicaltrials.gov\/study\/NCT04630769"},{"key":"11156_CR95","unstructured":"ClinicalTrials.gov. (2022). FT576 in subjects with multiple myeloma (NCT05182073). U.S. National Library of Medicine. Retrieved April 21, 2026, from https:\/\/clinicaltrials.gov\/study\/NCT05182073"},{"key":"11156_CR96","unstructured":"ClinicalTrials.gov. (2023). FT522 with rituximab in participants with relapsed\/refractory B-cell lymphoma (NCT05950334). U.S. National Library of Medicine. Retrieved April 21, 2026. https:\/\/clinicaltrials.gov\/study\/NCT05950334"},{"key":"11156_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115123","volume":"165","author":"X Lin","year":"2023","unstructured":"Lin, X., Sun, Y., Dong, X., Liu, Z., Sugimura, R., & Xie, G. (2023). IPSC-derived CAR-NK cells for cancer immunotherapy. Biomedicine & Pharmacotherapy, 165, Article 115123. https:\/\/doi.org\/10.1016\/j.biopha.2023.115123","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"1","key":"11156_CR98","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01575-0","volume":"17","author":"X Gong","year":"2024","unstructured":"Gong, X., Zhang, L., He, X., Yang, J., Li, X., Liu, W., Zhang, B., Tao, Z., & Qian, W. (2024). Novel natural killer cell-based therapies for hematologic and solid malignancies: Latest updates from ASCO 2024. Journal of Hematology & Oncology, 17(1), Article 57. https:\/\/doi.org\/10.1186\/s13045-024-01575-0","journal-title":"Journal of Hematology & Oncology"},{"key":"11156_CR99","unstructured":"Virgil, H. (2026). Ft596 and ft516 off-the-shelf, ipsc-derived nk cell products shows promise in b-cell lymphoma | cancernetwork. https:\/\/www.cancernetwork.com\/view\/ft596-and-ft516-off-the-shelf-ipsc-derived-nk-cell-products-shows-promise-in-b-cell-lymphoma"},{"key":"11156_CR100","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.coi.2018.03.013","volume":"51","author":"M Daher","year":"2018","unstructured":"Daher, M., & Rezvani, K. (2018). Next generation natural killer cells for cancer immunotherapy: The promise of genetic engineering. Current Opinion in Immunology, 51, 146\u2013153. https:\/\/doi.org\/10.1016\/j.coi.2018.03.013","journal-title":"Current Opinion in Immunology"},{"issue":"1","key":"11156_CR101","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.stem.2024.12.005","volume":"32","author":"A Kirkeby","year":"2025","unstructured":"Kirkeby, A., Main, H., & Carpenter, M. (2025). Pluripotent stem-cell-derived therapies in clinical trial: A 2025 update. Cell Stem Cell, 32(1), 10\u201337. https:\/\/doi.org\/10.1016\/j.stem.2024.12.005","journal-title":"Cell Stem Cell"},{"issue":"Supplement 1","key":"11156_CR102","doi-asserted-by":"publisher","first-page":"3873","DOI":"10.1182\/blood-2021-151520","volume":"138","author":"K Patel","year":"2021","unstructured":"Patel, K., Bachanova, V., Goodman, A. M., Pagel, J. M., Griffis, K., Anderson, M., Atwal, S., Bickers, C., Szabo, P., Wong, L., Chu, Y. W., Elstrom, R. L., & Strati, P. (2021). Phase I study of FT516, an off-the-shelf iPSC-derived NK cell therapy, in combination with rituximab in patients with relapsed\/refractory b-cell lymphoma. Blood, 138(Supplement 1), 3873. https:\/\/doi.org\/10.1182\/blood-2021-151520","journal-title":"Blood"},{"key":"11156_CR103","unstructured":"Fate Therapeutics (2021). Fate Therapeutics announces encouraging interim phase 1 data for iPSC-derived NK cell programs in relapsed\/refractory acute myeloid leukemia. Fate Therapeutics. Retrieved April 21, 2026, from https:\/\/ir.fatetherapeutics.com\/news-releases\/news-release-details\/fate-therapeutics-announces-encouraging-interim-phase-1-data"},{"key":"11156_CR104","unstructured":"Kasimati, M. (2021). Encouraging interim phase I data for FT516 and FT538 cellular products to treat R\/R AML. AML Hub. Retrieved April 21, 2026, from https:\/\/aml-hub.com\/medical-information\/encouraging-interim-phase-i-data-for-ft516-and-ft538-cellular-products-to-treat-rr-aml"},{"issue":"Supplement 1","key":"11156_CR105","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1182\/blood-2023-187192","volume":"142","author":"A Eckstrom","year":"2023","unstructured":"Eckstrom, A., Tyagi, A., Siddiqui, M., Mahmood, S., Wong, L., Valamehr, B. B., Daver, N., & Battula, V. L. (2023). FT538, iPSC-derived NK cells are potent inducers of apoptosis in AML cells and their effect is synergistic in combination with approved therapeutic strategies. Blood, 142(Supplement 1), 4817. https:\/\/doi.org\/10.1182\/blood-2023-187192","journal-title":"Blood"},{"issue":"24","key":"11156_CR106","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20246305","volume":"20","author":"MDC Ortu\u00f1o-Costela","year":"2019","unstructured":"Ortu\u00f1o-Costela, M. D. C., Cerrada, V., Garc\u00eda-L\u00f3pez, M., & Gallardo, M. E. (2019). The challenge of bringing ipscs to the patient. International Journal of Molecular Sciences, 20(24), Article 6305. https:\/\/doi.org\/10.3390\/ijms20246305","journal-title":"International Journal of Molecular Sciences"},{"key":"11156_CR107","doi-asserted-by":"publisher","DOI":"10.3389\/ebm.2025.10841","volume":"250","author":"Y Xiang","year":"2025","unstructured":"Xiang, Y., Dong, J., Shao, L., & Chen, S. (2025). Chimeric antigen receptor natural killer cell therapy for solid tumors: Mechanisms, clinical progress, and strategies to overcome the tumor microenvironment. Experimental Biology and Medicine, 250, Article 10841. https:\/\/doi.org\/10.3389\/ebm.2025.10841","journal-title":"Experimental Biology and Medicine"},{"issue":"6013","key":"11156_CR108","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1126\/science.1198687","volume":"331","author":"E Vivier","year":"2011","unstructured":"Vivier, E., Raulet, D. H., Moretta, A., Caligiuri, M. A., Zitvogel, L., Lanier, L. L., Yokoyama, W. M., & Ugolini, S. (2011). Innate or adaptive immunity? The example of natural killer cells. Science, 331(6013), 44\u201349. https:\/\/doi.org\/10.1126\/science.1198687","journal-title":"Science"},{"key":"11156_CR109","unstructured":"Fate Therapeutics (2021). Fate Therapeutics announces encouraging interim phase 1 data for iPSC-derived NK cell programs in relapsed\/refractory acute myeloid leukemia. Fate Therapeutics. Retrieved April 21, 2026, from https:\/\/ir.fatetherapeutics.com\/news-releases\/news-release-details\/fate-therapeutics-announces-encouraging-interim-phase-1-data"},{"key":"11156_CR110","unstructured":"Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion TM Edits. Retrieved November 2 (2023). from https:\/\/investors.centurytx.com\/news-releases\/news-release-details\/century-therapeutics-present-initial-clinical-data-supporting.html"},{"key":"11156_CR111","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.886429","volume":"13","author":"F Rossi","year":"2022","unstructured":"Rossi, F., Fredericks, N., Snowden, A., Allegrezza, M. J., & Moreno-Nieves, U. Y. (2022). Next generation natural killer cells for cancer immunotherapy. Frontiers in Immunology, 13, Article 886429. https:\/\/doi.org\/10.3389\/fimmu.2022.886429","journal-title":"Frontiers in Immunology"},{"issue":"7768","key":"11156_CR112","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41586-019-1410-1","volume":"572","author":"AM Paczulla","year":"2019","unstructured":"Paczulla, A. M., Rothfelder, K., Raffel, S., Konantz, M., Steinbacher, J., Wang, H., Tandler, C., Mbarga, M., Schaefer, T., Falcone, M., Nievergall, E., D\u00f6rfel, D., Hanns, P., Passweg, J. R., Lutz, C., Schwaller, J., Zeiser, R., Blazar, B. R., Caligiuri, M. A., \u2026 Lengerke, C. (2019). Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion. Nature, 572(7768), 254\u2013259. https:\/\/doi.org\/10.1038\/s41586-019-1410-1","journal-title":"Nature"},{"key":"11156_CR113","doi-asserted-by":"publisher","unstructured":"Rezvani, K., & Rouce, R. H. (2015). The application of natural killer cell immunotherapy for the treatment of cancer. Frontiers in Immunology, 6. https:\/\/doi.org\/10.3389\/fimmu.2015.00578","DOI":"10.3389\/fimmu.2015.00578"},{"issue":"8","key":"11156_CR114","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1016\/j.ymthe.2017.06.012","volume":"25","author":"K Rezvani","year":"2017","unstructured":"Rezvani, K., Rouce, R., Liu, E., & Shpall, E. (2017). Engineering natural killer cells for cancer immunotherapy. Molecular Therapy, 25(8), 1769\u20131781. https:\/\/doi.org\/10.1016\/j.ymthe.2017.06.012","journal-title":"Molecular Therapy"},{"issue":"8","key":"11156_CR115","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.tibtech.2015.05.001","volume":"33","author":"D Chakravarti","year":"2015","unstructured":"Chakravarti, D., & Wong, W. W. (2015). Synthetic biology in cell-based cancer immunotherapy. Trends in Biotechnology, 33(8), 449\u2013461. https:\/\/doi.org\/10.1016\/j.tibtech.2015.05.001","journal-title":"Trends in Biotechnology"},{"key":"11156_CR116","doi-asserted-by":"publisher","unstructured":"Lee, D. A. (2016). Regulatory considerations for nk cells used in human immunotherapy applications. In S. S. Somanchi (Ed.), Natural Killer Cells (Vol. Vol. 1441, pp. 347\u2013361). Springer. https:\/\/doi.org\/10.1007\/978-1-4939-3684-7_29","DOI":"10.1007\/978-1-4939-3684-7_29"},{"key":"11156_CR117","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1691743","volume":"16","author":"Y Feng","year":"2026","unstructured":"Feng, Y., Yang, Z., Zhou, Y., Liang, Y., & Zhao, H. (2026). From innate-like to innate: The next wave of off-the-shelf CAR immunotherapies. Frontiers in Immunology, 16, Article 1691743. https:\/\/doi.org\/10.3389\/fimmu.2025.1691743","journal-title":"Frontiers in Immunology"},{"key":"11156_CR118","unstructured":"Fate Therapeutics. (n.d.). Pipeline. Fate Therapeutics. Retrieved April 21 (2026). https:\/\/www.fatetherapeutics.com\/pipeline\/"},{"key":"11156_CR119","unstructured":"ClinicalTrials.gov. (2022). A study of CNTY-101 in participants with CD19-positive B-cell malignancies (NCT05336409). U.S. National Library of Medicine. Retrieved April 21, 2026, from https:\/\/clinicaltrials.gov\/study\/NCT05336409"},{"key":"11156_CR120","unstructured":"ClinicalTrials.gov. (2022). A trial to evaluate the safety and efficacy of NK cells in subjects with myelodysplastic syndromes (NCT05371730). U.S. National Library of Medicine. Retrieved April 21, 2026, from https:\/\/clinicaltrials.gov\/study\/NCT05371730"},{"key":"11156_CR121","unstructured":"ClinicalTrials.gov. (2024). A trial to evaluate the safety and efficacy of NCR300 in preventing recurrence of acute myeloid leukemia (AML) after transplantation (NCT06441084). U.S. National Library of Medicine. Retrieved April 21, 2026, from https:\/\/clinicaltrials.gov\/study\/NCT06441084"},{"key":"11156_CR122","unstructured":"ClinicalTrials.gov. (2022). FT576 in subjects with multiple myeloma (NCT05182073). U.S. National Library of Medicine. Retrieved April 21, 2026, from https:\/\/clinicaltrials.gov\/study\/NCT05182073"},{"key":"11156_CR123","unstructured":"ClinicalTrials.gov. (2023). FT522 with rituximab in participants with relapsed\/refractory B-cell lymphoma (NCT05950334). U.S. National Library of Medicine. Retrieved April 21, 2026, from https:\/\/clinicaltrials.gov\/study\/NCT05950334"}],"container-title":["Stem Cell Reviews and Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12015-026-11156-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12015-026-11156-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12015-026-11156-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T07:27:39Z","timestamp":1783668459000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12015-026-11156-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":123,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["11156"],"URL":"https:\/\/doi.org\/10.1007\/s12015-026-11156-y","relation":{},"ISSN":["2629-3269","2629-3277"],"issn-type":[{"value":"2629-3269","type":"print"},{"value":"2629-3277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"25 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}